Late diagnosis of primary hyperaldosteronism in outpatient practice

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Timely diagnosis of resistant arterial hypertension (AH) and, as a consequence, detection of primary hyperaldosteronism (PHA) are remaining to be a serious problem in outpatient practice. This happens due to insufficient awareness of these nosologies among primary care physicians, often incompletely collected anamnesis and insufficient knowledge of modern diagnostic and treatment algorithms. Clinical case described in the article clearly illustrates the consequences of PHA late diagnosis in a young female patient. The absence of a correct diagnosis during 10 years resulted in persistent uncontrolled arterial hypertension and development of target organ damage. This observation highlights the importance of increased vigilance for PHA in patients with treatment-resistant arterial hypertension.

Full Text

Restricted Access

About the authors

Ekaterina S. Shcherbina

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)

Email: esscherbina@inbox.ru
ORCID iD: 0000-0001-8619-8123
SPIN-code: 6888-7050

MD, postgraduate student, assistant at the Department of outpatient therapy of the Institute of Clinical Medicine

Russian Federation, 117513, Moscow, 1/6 Ostrovityanova St.

Vera N. Larina

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)

Author for correspondence.
Email: larinav@mail.ru
ORCID iD: 0000-0001-7825-5597
SPIN-code: 3674-9620

Dr. Sci. (Medicine), professor, head of the Department of outpatient therapy of the Institute of Clinical Medicine

Russian Federation, 117513, Moscow, 1/6 Ostrovityanova St.

References

  1. Баланова Ю.А., Драпкина О.М., Куценко В.А., Имаева А.Э., Концевая А.В., Максимов С.А. с соавт. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(S8):105–120. [Balanova YuA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya AV, Maksimov SA et al. Hypertension in the Russian population during the COVID-19 pandemic: Sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(S8):105–120 (In Russ.)].EDN: YRUNUX. https://doi.org/10.15829/1728-8800-2023-3785
  2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.PMID: 34450083. PMCID: PMC8446938. https://doi.org/10.1016/S0140-6736(21)01330-1
  3. Xu Z, Yang J, Hu J, Song Y, He W, Luo T et al.; Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913–22.PMID: 32327102. https://doi.org/10.1016/j.jacc.2020.02.052
  4. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al.; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–2300.PMID: 17161262. https://doi.org/10.1016/j.jacc.2006.07.059
  5. Клинические рекомендации. Артериальная гипертензия у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», Общероссийская общественная организация «Российское научное медицинское общество терапевтов». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 62_3. Доступ: https://cr.minzdrav.gov.ru/preview-cr/62_3 (дата обращения – 25.04.2025). [Clinical guidelines. Arterial hypertension in adults. Russian Society of Cardiology, Russian Scientific Medical Society of Internal Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 62_3. URL: https://cr.minzdrav.gov.ru/preview-cr/62_3 (date of access – 25.04.2025) (In Russ.)].
  6. Клинические рекомендации. Первичный гиперальдостеронизм. Общероссийская общественная организация «Российская ассоциация эндокринологов». Доступ: https://endoinfo.ru/upload/kr_pga_20.09.2021_4.pdf (дата обращения – 25.04.2025). [Clinical guidelines. Primary hyperaldosteronism. Russian Association of Endocrinology. URL: https://endoinfo.ru/upload/kr_pga_20.09.2021_4.pdf (date of access – 25.04.2025) (In Russ.)].
  7. Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H et al. Screening for primary aldosteronism in hypertensive subjects: Results from two German epidemiological studies. Eur J Endocrinol. 2012;167(1):7–15.PMID: 22495491. https://doi.org/10.1530/eje-11-1013
  8. Chao С-T, Wu V-C, Kuo C-C, Lin Y-H, Chang C-C, Chueh SJ et al. Diagnosis and management of primary aldosteronism: An updated review. Ann Med. 2013;45(4):375–83.PMID: 23701121. https://doi.org/10.3109/07853890.2013.785234
  9. Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system, and hypertension. Am J Hyperten. 2021;34(1):15–27.PMID: 32820797. PMCID: PMC7891246. https://doi.org/10.1093/ajh/hpaa137
  10. Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2-03):84–92.PMID: 30165708. https://doi.org/10.1055/a-0672-0836
  11. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: Mechanistic links. Nat Rev Nephrol. 2019;15(6):367–85.PMID: 31015582. PMCID: PMC7278043. https://doi.org/10.1038/s41581-019-0145-4
  12. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50.PMID: 29129575. https://doi.org/10.1016/S2213-8587(17)30319-4
  13. Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.PMID: 15001583. https://doi.org/10.1210/jc.2003-031337
  14. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M-C et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38(10):1919–28.PMID: 32890264. https://doi.org/10.1097/ HJH.0000000000002510
  15. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916.PMID: 26934393. https://doi.org/10.1210/jc.2015-4061
  16. Young WF Jr. Diagnosis and treatment of primary aldosteronism: Practical clinical perspectives. J Intern Med. 2019;285(2):126–48.PMID: 30255616. https://doi.org/10.1111/joim.12831
  17. Zhu R, Shagjaa T, Rossitto G, Caroccia B, Seccia TM, Gregori D, Rossi GP. Exclusion tests in unilateral primary aldosteronism (ExcluPA) study. J Clin Endocrinol Metab. 2023;108(2):496–506.PMID: 36373399. https://doi.org/10.1210/clinem/dgac654
  18. Leung AA, Symonds CJ, Hundemer GL, Ronksley PE, Lorenzetti DL, Pasieka JL et al. Performance of confirmatory tests for diagnosing primary aldosteronism: A systematic review and meta-analysis. Hypertension. 2022;79(8):1835–44.PMID: 35652330. PMCID: PMC9278709. https://doi.org/10.1161/hypertensionaha.122.19377
  19. Демидова Т.Ю., Титова В.В. Сложности диагностики первичного гиперальдостеронизма. FOCUS Эндокринология. 2023;4(2):59–68. [Demidova TYu, Titova VV. Difficulties in diagnosing primary hyperaldosteronism. FOCUS Endokrinologiya = FOCUS Endocrinology. 2023;4(2):59–68 (In Russ.)].EDN: ZIIQBY. https://doi.org/10.15829/1560-4071-2023-12
  20. Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C et al.; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689–99.PMID: 28576687. PMCID: PMC5572673. https://doi.org/10.1016/S2213-8587(17)30135-3
  21. Ладыгина Д.О., Вастистова А.А., Шиленкова Е.С., Платонова Н.М., Бельцевич Д.Г., Фадеев В.В. Первичный гиперальдостеронизм: существующие проблемы и возможные решения. Фарматека. 2024;31(2):8–17. [Ladygina DO, Vastistova AA, Shilenkova ES, Platonova NM, Beltsevich DG, Fadeev VV. Primary hyperaldosteronism: Current problems and possible solutions. Farmateka. 2024;31(2):8–17 (In Russ.)].EDN: XXGVLG. https://dx.doi.org/10.18565/pharmateca.2024.2.8-17
  22. Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study. Hypertension. 2022;79(1):178–86.PMID: 34657442. PMCID: PMC8664996. https://doi.org/10.1161/hypertensionaha.121.18118
  23. Jaffle G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension. 2020;75(3):650–59.PMID: 32008436. https://doi.org/10.1161/hypertensionaha.119.14359
  24. Zekarias K, Tessier KM. Screening rate for primary aldosteronism among patients with treatment-resistant hypertension: Retrospective analysis of current practice. Endocr Pract. 2022;28(3):271–75.PMID: 34843971. PMCID: PMC8901447. https://doi.org/10.1016/j.eprac.2021.11.085
  25. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820–25.PMID: 3661395. https://doi.org/10.1016/0002-9149(87)91030-7

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. Timeline of disease development in the observed patient

Download (152KB)

Copyright (c) 2025 Bionika Media